Polyneuron Pharmaceuticals AG
Polyneuron is a pharmaceutical company, committed to the development of a new drug class for the treatment of autoimmune disorders.
Polyneuron Pharmaceuticals AG has raised €33M across 2 funding rounds from 2 investors, most recently a Series A round in Sep 2020. Based in Basel, Switzerland; founded 2014; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€33M
€32,967,765
Funding rounds
2
Investors
2
distinct backers
Active since
2019-01
latest 2020-09
Funding by year
EUR raised per yearPolyneuron Pharmaceuticals AG — funding by year — interactive chart.
Data table
| Polyneuron Pharmaceuticals AG — funding by year | |
|---|---|
| 2018 | €20M |
| 2020 | €13M |
Signals
Medium confidenceRaise-next likelihood8
base rate 44% for Series A
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Down/flat last round
Exit likelihood9
base rate 11% (2+ rounds)
- ▲ €30M+ raised
- ▼ No recent equity round (debt-only or quiet)
Timing: dormant vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-09-16 | Series A | €13M | — | View deal → |
| 2019-01-01 | Other | €20M | New Enterprise Associates,Sofinnova Partners | View deal → |
Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData